Company news
Theralink Technologies Inc. news in 2017
Theralink Technologies Inc.'s news releases, calls and decks from 2017, newest first.
One-Year Follow-Up Shows 71.4% Progression-Free Survival in 14 Prostate Cancer Patients Treated with ProscaVax in Phase 1 Clinical Trial
December 21, 2017
100% of Prostate Cancer Patients Completing 31-Week Post-Therapy Exam After Treatment with OncBioMune Immunotherapy Show No Disease Progression
December 5, 2017
80% of Prostate Cancer Patients in OncBioMune Phase 1 Clinical Trial of ProscaVax Show No Disease Progression at the First Post-Therapy Follow-up
November 13, 2017
OncBioMune Preparing to Initiate Trials of Novel Therapeutic Ovarian Cancer Vaccine
October 17, 2017
OncBioMune CMO Producing First Batch of Tretinoin for Acute Promyelocytic Leukemia
September 29, 2017
OncBioMune Meets Primary Objective in Trial of ProscaVax Immunotherapy Vaccine for Prostate Cancer
September 14, 2017
OncBioMune Awaits Approval from Regulatory Committee to Commence Phase 2 Trial of ProscaVax as Front Line Prostate Cancer Treatment
August 31, 2017
OncBioMune to Present Abstract on Clinical Trial of Novel Prostate Cancer Vaccine at American Association of Cancer Research Special Conference
August 29, 2017
Final Patient Completes Treatment in OncBioMune Clinical Trial of ProscaVax for Prostate Cancer
August 24, 2017
OncBioMune Submits Documents Necessary to Commercialize Norepinefrine for Low Blood Pressure and Heart Failure in Mexico
August 22, 2017
OncBioMune To Become Exclusive Distributor of Lipomed Drugs in Mexico
August 10, 2017
OncBioMune Submits Application to Commercialize Anti-Rabies Drug in Mexico
August 3, 2017
OncBioMune Acquires Propolis Product Line for German Partner
July 20, 2017
Phase 2 Trial of ProscaVax for Early-Stage Prostate Cancer Nears Commencement
July 13, 2017
OncBioMune Pharmaceuticals Establishes Another Revenue Stream; Schedules First Patient with AAT Deficiency for Treatment in Mexico
June 28, 2017
Enrollment to Begin in OncBioMune's Trial of ProscaVax for Prostate Cancer in Mexico
June 27, 2017
OncBioMune Receives Patent Protecting Novel Cancer Vaccine in Mexico
June 21, 2017
OncBioMune Awarded Patent for ProscaVax in Japan
June 20, 2017
OncBioMune Acquires Norepinefrine for Low Blood Pressure and Heart Failure in Mexico from Teva Pharmaceuticals Mexico
June 19, 2017
OncBioMune, AqVida add additional drugs to distribution agreement (Paclitaxel and Oxaliplatin)
June 15, 2017
OncBioMune Protects ProscaVax Cancer Treatment Technology in Hong Kong
June 7, 2017
OncBioMune's Andfrt(R) Shown in Clinical Trial to Improve Sperm Count and Mobility
June 6, 2017
Protocol Submitted to FDA for Phase 2 Clinical Trial of ProscaVax as Immunotherapy for Early-Stage Prostate Cancer
June 1, 2017
OncBioMune Reports Record Monthly Sales for Bekunis(R) in May
May 31, 2017
OncBioMune Receives Approval for Male Fertility Product in Mexico
May 30, 2017
OncBioMune CMO Begins Formulation Work on Tretinoin for Acute Promyelocytic Leukemia
May 23, 2017
OncBioMune Provides Corporate Update, Nearly 50 Drug Candidates in Pipeline or Being Negotiated
May 9, 2017
OncBioMune Completes Enrollment in Phase 1 Trial of ProscaVax for Prostate Cancer
May 3, 2017
OncBioMune, AqVida Partner for Commercializing Cancer and Other Generic Drugs in Mexico
April 26, 2017
OncBioMune Licenses Tretinoin for the Treatment of Acute Promyelocytic Leukemia Throughout Mexico, Central and Latin America
April 20, 2017
OncBioMune Prepares Submission Seeking Marketing Approval for Anti-D Immunoglobulin in Mexico
April 18, 2017
OncBioMune and Gem Pharmaceuticals Finalizing Partnership Terms to Develop New Cancer Drug for Mexico, Central and Latin America Markets
March 30, 2017
OncBioMune Sales of Bekunis(R) and Cirkused(R) Exceed Forecast by 164 Percent in First Six Months on Market
March 27, 2017
OncBioMune Announces Term Sheet to Acquire Norepinefrine from Teva Pharmaceuticals in Mexico
March 20, 2017
OncBioMune Announces Term Sheet with EOC Pharma for Development of Telatinib
March 14, 2017
OncBioMune Acquires Vitel Laboratorios, Gains Two Revenue Generating Drugs, Robust Pipeline and Extensive Distribution Network
March 13, 2017
OncBioMune Announces Cancer Vaccine Poster Presentation at the 2017 American Association for Cancer Research Meeting
February 2, 2017
Latest Clinical Data from OncBioMune Supports Safety and Therapeutic Profile of ProscaVax for Prostate Cancer for Upcoming Phase 2 Clinical Trials
January 26, 2017
Departments of Urology and Oncology Approve Protocol for OncBioMune's Phase 2/3 Trial of ProscaVax for Prostate Cancer in Mexico
January 18, 2017
OncBioMune Submitting Clinical Trial of World's First Early-Stage Prostate Cancer Vaccine to The Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute
January 10, 2017